Developer docs
API playgroundTry for free, no card

Search company profiles

SHL Telemedicine

Full company profile

uuid0033y49

Namestring
SHL Telemedicine
Legal namestring
SHL Telemedicine Ltd.
Company typeenum
Public
Founded yearint
1987
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote cardiac monitoring, telemedicine services, mobile ECG devices, chronic disease monitoring, telehealth platforms
Industry6 codes
1Cardiology Telemedicine Platforms
CodeHLALAGABPrimaryYes
2Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
CodeHLALADADPrimaryNo
3Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
CodeHLACAPAIPrimaryNo
4Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
CodeHLACAPABPrimaryNo
5Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
CodeHLACAPAKPrimaryNo
6ECG/EKG & Heart Rhythm Monitors (Consumer)
CodeCRACAQACPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Services for the Elderly and Persons with Disabilities624120
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Health Services8000
Product category
Remote Cardiac and Chronic Disease Telemedicine Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Telemedicine Services Revenue
TypeSubscription Recurring
Description

SHL generates revenue primarily through telemedicine monitoring services provided to health insurers, payers, hospitals, and directly to patients. Services include 24/7 cardiac monitoring, chronic disease management for CHF and COPD patients, and acute cardiac care programs. Revenue from 2025 was USD 58,694 thousand.

shl-telemedicine.com
2Medical Device Sales
TypeHardware Sales
Description

Sale of FDA-cleared medical devices including SmartHeart Pro, CardioSen'C, Cardio'B, TelePress, TeleWeight, TeleBreather, and TelePulse Oximeter. These devices are sold directly to consumers and through healthcare provider partnerships.

shl-telemedicine.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of SmartHeart technology to healthcare partners including Mayo Clinic, CVS Health, VNA Care, ChristianaCare, and Post-Acute Medical for use across different platforms and clinical settings.

shl-telemedicine.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1B2B Telemedicine Services
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Services provided to health insurers, payers, hospitals and physicians under contractual arrangements. Pricing is negotiated per contract and not publicly disclosed.

shl-telemedicine.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 9 records shown
1SmartHeartPro
Description

FDA cleared hospital-grade 12-lead ECG platform for professional use

shl-telemedicine.com
+8 more records
Core offering1 text field

SHL Telemedicine provides remote cardiac and chronic disease monitoring services via its cloud-based telemedicine platform and FDA-cleared 12-lead ECG devices (SmartHeart, CardioSen'C, Cardio'B). The company operates 24/7 monitoring centers staffed by medical professionals that receive, interpret, and act on ECG and vital signs transmissions from patients at home. Its offerings are sold both as enterprise contracts to health insurers, payers, and hospitals and as OTC consumer devices via retail channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Extended clinical study by Israeli Heart Society concludes that SHL service significantly increases probability of users surviving the first year after a heart attack
+3 more records
Product overview1 text field

SHL Telemedicine offers a comprehensive telemedicine platform combining FDA-cleared mobile 12-lead ECG devices with 24/7 monitoring services. The core portfolio includes SmartHeart®/SmartHeartPro© (FDA-cleared hospital-grade 12-lead ECG with cloud-based data and 15-minute turnaround), CardioSen'C™ (cellular-digital ECG transmitter), Cardio'B™ (ergonomic portable ECG), and CardioBeeper 12/12™ (telephone-line ECG). Supporting monitoring devices include TelePress™ (blood pressure), TeleWeight™ (weight), TeleBreather™ (lung function), and TelePulse Oximeter (oxygen saturation), all connected via the CCM™ Central Communication Module. The platform is complemented by 24/7 telemedicine centers in Israel and Germany providing professional medical staff monitoring and Personal Health Records. The system uses AI and big data to detect anomalies and trigger alerts when patient vital signs deviate from baselines.

Product and service11 records
1SmartHeart / SmartHeartPro
CategoryMobile ECG device
Description

FDA-cleared mobile hospital-grade 12-lead ECG device for personal use that enables detection of heart attacks without assistance from a medical professional. Data is stored in the cloud and is HIPAA compliant, with 24/7 telemedicine center support and 15-minute ECG report turnaround. Sold to health insurers, hospitals, and directly to consumers via retail channels.

2CardioSen'C
CategoryMobile ECG device
Description

First personal cellular-digital 12-lead ECG transmitter that sends a patient's complete 12-lead ECG and rhythm read-out strip in real time to a medical monitoring center for evaluation of arrhythmia, ischemia, and myocardial infarction.

3Cardio'B
CategoryMobile ECG device
Description

Lightest portable 12-lead ECG transmitter device of its kind, designed for ECG transmissions from home, office, and on the go. Features ergonomic design, acoustic transmission via any phone connection, and user-friendly operation with less than a minute transmission time.

4CardioBeeper 12/12
CategoryMobile ECG device
Description

FDA-cleared hand-held ECG transmitter for personal use that transmits a full 12-lead ECG via standard telephone line in seconds, enabling real-time diagnosis of arrhythmia, ischemia, and myocardial infarction.

5CCM (Central Communication Module)
CategoryCommunication module / connectivity
Description

Innovative telecommunication device that transmits medical data from SHL monitoring devices to telemedicine centers. Supports Internet, cellular, or landline transmission with compact plug-and-play design, no control buttons, automatic data encryption, and remote software updates.

6TelePress
CategoryRemote vital signs monitoring
Description

Remote blood pressure monitoring device for personal use with one-touch automatic self-pressurization. Measures heart rate and systolic and diastolic values, with real-time response to abnormal measurements and early identification of unfavorable trends.

7TeleWeight
CategoryRemote vital signs monitoring
Description

Trans-telephonic weight monitoring device that automatically measures and transmits weight data to the medical monitoring center, designed to detect fluid accumulation in the body and trigger alerts for congestive heart failure patients.

8TeleBreather
CategoryRemote vital signs monitoring
Description

Remote handheld device for testing lung function by measuring air volumes expelled during exhalation and exhalation speed, intended for COPD and chronic lung condition patients.

9TelePulse Oximeter
CategoryRemote vital signs monitoring
Description

Handheld diagnostic device for measuring blood oxygen saturation (SpO2) and pulse rate at home, intended for chronic lung-heart disease patients including COPD.

1024/7 Telemedicine Monitoring Centers
CategoryTelemedicine monitoring service
Description

24/7 telemedicine centers staffed by professional medical teams that provide immediate feedback, reassurance, emergency facilitation, and hospital coordination for patients using SHL devices. Located in Israel and Germany and processing approximately 3 million medical interactions per year.

11Personal Health Records
CategoryDigital health platform
Description

Online secured personal health records containing demographic data, medical history, ECG results, blood pressure readings, weight measurements, medication data, and hospitalization records, accessible to patients and physicians.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

SHL subsidiary Mediton awarded continued provision of services to Israeli Ministry of Defense, representing ongoing government partnership for healthcare services.

2BNK (German Society of Cardiologists in Private Practice)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-26
Description

Collaboration agreement across Germany for use of SHL Telemedicine services, integrating SHL technology into cardiologists' private practice workflows.

shl-telemedicine.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-14
Description

Collaboration using SmartHeart 12 lead ECG Technology for post-acute care settings, expanding access to cardiac monitoring in rehabilitation and post-hospital recovery environments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-11
Description

Agreement for use of SmartHeart full 12 lead ECG technology. ChristianaCare is among the largest regional heart centers on the East Coast, enabling broad patient access to cardiac monitoring services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Large contract for providing Telehealth Services to Geriatric Patients, expanding SHL's presence in the German geriatric care market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-18
Description

Agreement for use of SmartHeart full 12 lead ECG technology. CVS Health later expanded the use of SmartHeart technology, demonstrating successful partnership and product validation in retail healthcare settings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

SHL closed acquisition of 70% of Mediton Group companies (leading B2B healthcare services provider in Israel) in September 2021. In March 2025, SHL acquired the remaining stake, achieving 100% ownership. Mediton provides additional B2B healthcare services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-19
Description

Multi-year large Chronic Disease Telehealth contract awarded following a tender to provide service to congestive heart failure (CHF) patients. Tens of thousands of SHL home systems installed across Germany.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-07
Description

BARMER health insurance company announced that all of its insureds in Germany will have access to the video consultation doctors' virtual visit service provided by SHL Telemedicine.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-17
Description

Collaboration for use of SmartHeart 12 Lead ECG technology in VNA Care's home health care services. Helps individuals return home from hospital sooner and manage newly diagnosed illnesses.

11Jumedi GmbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-25
Description

SHL German subsidiary closed acquisition of 100% of Jumedi GmbH, a developer of Digital Health technologies, strengthening leadership of German operation and adding digital health development capabilities.

shl-telemedicine.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-30
Description

Strategic collaboration for use of SmartHeart technology across different platforms. SmartHeart is already being used at Mayo Clinic and will now be implemented for broader use. This partnership validates SHL's technology through one of the world's leading healthcare systems.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Heartbeat Health is a US virtual cardiology platform offering remote cardiac care, ECG review, and chronic disease management programs. Comparable to SHL's payor- and provider-channel telehealth cardiology services, though more US-centric and earlier stage.

TypeEmerging player
Description

Biotricity is a smaller US-based remote cardiac monitoring company offering devices and RPM services for arrhythmia and chronic disease. Comparable to SHL in providing connected cardiac RPM with subscription analytics, but at a meaningfully smaller scale and narrower commercial footprint.

TypeBroad incumbent
Description

Boston Scientific acquired Preventice Solutions, a US provider of ambulatory ECG monitors and connected cardiac diagnostics. Comparable to SHL in providing connected cardiac monitoring with central interpretation, but operates within Boston Scientific's much broader interventional and structural heart franchise.

TypeEmerging player
Description

Eko Health produces FDA-cleared digital stethoscopes and AI-powered cardiac decision support, including the CORE 500 digital stethoscope with embedded ECG. Overlaps with SHL in AI-driven cardiac auscultation and rhythm analysis, but Eko focuses on clinician-side tools rather than direct-to-patient 12-lead monitoring.

TypeDirect peer
Description

iRhythm Technologies is a US-based cardiac ambulatory monitoring company known for the Zio long-term ECG patch and AI-based arrhythmia detection. Comparable to SHL in serving cardiology patients with continuous remote ECG monitoring and central interpretation services, though SHL emphasizes 12-lead mobile ECG while iRhythm emphasizes patch-based extended wear.

TypeDirect peer
Description

AliveCor manufactures KardiaMobile, an FDA-cleared personal ECG device including the 6-lead KardiaMobile 6L, and is the closest direct competitor to SHL's SmartHeart in the consumer/clinical personal 12-6 lead ECG category. Both companies target cardiology-focused remote monitoring but AliveCor leans consumer/OTC while SHL anchors payor and clinical provider channels.

TypeEmerging player
Description

Withings produces consumer health devices including the ScanWatch with embedded single-lead ECG and SpO2. Comparable to SHL in bringing clinical-grade vitals/ECG to the consumer home, but distributes through a consumer-electonics retail channel rather than payor/clinical contracting.

TypeBroad incumbent
Description

Medtronic's Cardiac Diagnostics business — including the Reveal LINQ insertable cardiac monitor and connected diagnostics services — represents a large incumbent in remote cardiac monitoring with implantable and external devices. Comparable to SHL for ECG-based remote diagnostics, though Medtronic spans implantable CRM and broader hospital capital equipment.

TypeBroad incumbent
Description

Royal Philips acquired BioTelemetry to enter ambulatory cardiac monitoring (mobile cardiac telemetry, event monitoring, Holter). As a large medical-device incumbent, Philips competes with SHL in cardiac remote monitoring via established hospital and payor channels, but offers a much broader clinical product portfolio beyond SHL's specialty focus.

TypeBroad incumbent
Description

GE HealthCare's cardiology portfolio includes diagnostic ECG, cardiac ultrasound, and patient monitoring solutions widely deployed in hospitals. Comparable to SHL as a provider of clinical-grade ECG and cardiac monitoring infrastructure, though GE operates primarily in hospital capital equipment rather than payor-funded home telemedicine.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SHL Telemedicine

Remote Cardiac and Chronic Disease Telemedicine Servicesshl-telemedicine.com

SHL Telemedicine firmographics

Firmographics
Name
SHL Telemedicine
Legal name
SHL Telemedicine Ltd.
Website
https://shl-telemedicine.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

SHL Telemedicine industry classification

Industry
Product category
Remote Cardiac and Chronic Disease Telemedicine Services
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Services for the Elderly and Persons with Disabilities (624120)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)
akta.pro primary industry
Cardiology Telemedicine Platforms (HLALAGAB)
akta.pro secondary industries
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC)

Keywords

  • Remote cardiac monitoring
  • Telemedicine services
  • Mobile ECG devices
  • Chronic disease monitoring
  • Telehealth platforms

Where SHL Telemedicine is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

SHL Telemedicine business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Telemedicine Services Revenue: SHL generates revenue primarily through telemedicine monitoring services provided to health insurers, payers, hospitals, and directly to patients. Services include 24/7 cardiac monitoring, chronic disease management for CHF and COPD patients, and acute cardiac care programs. Revenue from 2025 was USD 58,694 thousand.
  2. Medical Device Sales: Sale of FDA-cleared medical devices including SmartHeart Pro, CardioSen'C, Cardio'B, TelePress, TeleWeight, TeleBreather, and TelePulse Oximeter. These devices are sold directly to consumers and through healthcare provider partnerships.
  3. Technology Licensing: Licensing of SmartHeart technology to healthcare partners including Mayo Clinic, CVS Health, VNA Care, ChristianaCare, and Post-Acute Medical for use across different platforms and clinical settings.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractB2B Telemedicine Services

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

SHL Telemedicine product offering

Product offering

Core offering

SHL Telemedicine provides remote cardiac and chronic disease monitoring services via its cloud-based telemedicine platform and FDA-cleared 12-lead ECG devices (SmartHeart, CardioSen'C, Cardio'B). The company operates 24/7 monitoring centers staffed by medical professionals that receive, interpret, and act on ECG and vital signs transmissions from patients at home. Its offerings are sold both as enterprise contracts to health insurers, payers, and hospitals and as OTC consumer devices via retail channels.

Product overview

SHL Telemedicine offers a comprehensive telemedicine platform combining FDA-cleared mobile 12-lead ECG devices with 24/7 monitoring services. The core portfolio includes SmartHeart®/SmartHeartPro© (FDA-cleared hospital-grade 12-lead ECG with cloud-based data and 15-minute turnaround), CardioSen'C™ (cellular-digital ECG transmitter), Cardio'B™ (ergonomic portable ECG), and CardioBeeper 12/12™ (telephone-line ECG). Supporting monitoring devices include TelePress™ (blood pressure), TeleWeight™ (weight), TeleBreather™ (lung function), and TelePulse Oximeter (oxygen saturation), all connected via the CCM™ Central Communication Module. The platform is complemented by 24/7 telemedicine centers in Israel and Germany providing professional medical staff monitoring and Personal Health Records. The system uses AI and big data to detect anomalies and trigger alerts when patient vital signs deviate from baselines.

Differentiator

Problem solved

Functional benefit

Brands

  • SmartHeartPro: FDA cleared hospital-grade 12-lead ECG platform for professional use
  • SmartHeart
  • TelePress
  • CardioSen'C
  • Cardio'B
  • CCM
  • TeleWeight
  • TeleBreather
  • TelePulse Oximeter

Products and services

  • SmartHeart / SmartHeartPro FDA-cleared mobile hospital-grade 12-lead ECG device for personal use that enables detection of heart attacks without assistance from a medical professional. Data is stored in the cloud and is HIPAA compliant, with 24/7 telemedicine center support and 15-minute ECG report turnaround. Sold to health insurers, hospitals, and directly to consumers via retail channels.
  • CardioSen'C First personal cellular-digital 12-lead ECG transmitter that sends a patient's complete 12-lead ECG and rhythm read-out strip in real time to a medical monitoring center for evaluation of arrhythmia, ischemia, and myocardial infarction.
  • Cardio'B Lightest portable 12-lead ECG transmitter device of its kind, designed for ECG transmissions from home, office, and on the go. Features ergonomic design, acoustic transmission via any phone connection, and user-friendly operation with less than a minute transmission time.
  • CardioBeeper 12/12 FDA-cleared hand-held ECG transmitter for personal use that transmits a full 12-lead ECG via standard telephone line in seconds, enabling real-time diagnosis of arrhythmia, ischemia, and myocardial infarction.
  • CCM (Central Communication Module) Innovative telecommunication device that transmits medical data from SHL monitoring devices to telemedicine centers. Supports Internet, cellular, or landline transmission with compact plug-and-play design, no control buttons, automatic data encryption, and remote software updates.
  • TelePress Remote blood pressure monitoring device for personal use with one-touch automatic self-pressurization. Measures heart rate and systolic and diastolic values, with real-time response to abnormal measurements and early identification of unfavorable trends.
  • TeleWeight Trans-telephonic weight monitoring device that automatically measures and transmits weight data to the medical monitoring center, designed to detect fluid accumulation in the body and trigger alerts for congestive heart failure patients.
  • TeleBreather Remote handheld device for testing lung function by measuring air volumes expelled during exhalation and exhalation speed, intended for COPD and chronic lung condition patients.
  • TelePulse Oximeter Handheld diagnostic device for measuring blood oxygen saturation (SpO2) and pulse rate at home, intended for chronic lung-heart disease patients including COPD.
  • 24/7 Telemedicine Monitoring Centers 24/7 telemedicine centers staffed by professional medical teams that provide immediate feedback, reassurance, emergency facilitation, and hospital coordination for patients using SHL devices. Located in Israel and Germany and processing approximately 3 million medical interactions per year.
  • Personal Health Records Online secured personal health records containing demographic data, medical history, ECG results, blood pressure readings, weight measurements, medication data, and hospitalization records, accessible to patients and physicians.

Quantifiable outcome

  • Extended clinical study by Israeli Heart Society concludes that SHL service significantly increases probability of users surviving the first year after a heart attack
  • +3 more outcomes

Companies that use SHL Telemedicine

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles3 records

SHL Telemedicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

SHL Telemedicine partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Israeli Ministry of DefensecoreStrategic or Co-development Partner · 24 June 2026SHL subsidiary Mediton awarded continued provision of services to Israeli Ministry of Defense, representing ongoing government partnership for healthcare services.
  • BNK (German Society of Cardiologists in Private Practice)coreStrategic or Co-development Partner · 26 April 2022Collaboration agreement across Germany for use of SHL Telemedicine services, integrating SHL technology into cardiologists' private practice workflows.
  • Post-Acute MedicalcoreStrategic or Co-development Partner · 14 February 2022Collaboration using SmartHeart 12 lead ECG Technology for post-acute care settings, expanding access to cardiac monitoring in rehabilitation and post-hospital recovery environments.
  • ChristianaCarecoreStrategic or Co-development Partner · 11 November 2021Agreement for use of SmartHeart full 12 lead ECG technology. ChristianaCare is among the largest regional heart centers on the East Coast, enabling broad patient access to cardiac monitoring services.
  • AOK Rheinland-Pfalz/SaarlandcoreStrategic or Co-development Partner · 1 November 2021Large contract for providing Telehealth Services to Geriatric Patients, expanding SHL's presence in the German geriatric care market.
  • CVS Health / CVS Pharmacy Inc.coreStrategic or Co-development Partner · 18 October 2021Agreement for use of SmartHeart full 12 lead ECG technology. CVS Health later expanded the use of SmartHeart technology, demonstrating successful partnership and product validation in retail healthcare settings.
  • Mediton GroupcoreStrategic or Co-development Partner · 1 September 2021SHL closed acquisition of 70% of Mediton Group companies (leading B2B healthcare services provider in Israel) in September 2021. In March 2025, SHL acquired the remaining stake, achieving 100% ownership. Mediton provides additional B2B healthcare services.
  • AOK BayerncoreStrategic or Co-development Partner · 19 July 2021Multi-year large Chronic Disease Telehealth contract awarded following a tender to provide service to congestive heart failure (CHF) patients. Tens of thousands of SHL home systems installed across Germany.
  • BARMERcoreStrategic or Co-development Partner · 7 July 2021BARMER health insurance company announced that all of its insureds in Germany will have access to the video consultation doctors' virtual visit service provided by SHL Telemedicine.
  • VNA CarecoreStrategic or Co-development Partner · 17 June 2021Collaboration for use of SmartHeart 12 Lead ECG technology in VNA Care's home health care services. Helps individuals return home from hospital sooner and manage newly diagnosed illnesses.
  • Jumedi GmbHminorStrategic or Co-development Partner · 25 January 2021SHL German subsidiary closed acquisition of 100% of Jumedi GmbH, a developer of Digital Health technologies, strengthening leadership of German operation and adding digital health development capabilities.
  • Mayo CliniccoreStrategic or Co-development Partner · 30 August 2020Strategic collaboration for use of SmartHeart technology across different platforms. SmartHeart is already being used at Mayo Clinic and will now be implemented for broader use. This partnership validates SHL's technology through one of the world's leading healthcare systems.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

SHL Telemedicine competitors and assessment

Company assessment

Emerging players

  • Heartbeat Health: Heartbeat Health is a US virtual cardiology platform offering remote cardiac care, ECG review, and chronic disease management programs. Comparable to SHL's payor- and provider-channel telehealth cardiology services, though more US-centric and earlier stage.
  • Biotricity: Biotricity is a smaller US-based remote cardiac monitoring company offering devices and RPM services for arrhythmia and chronic disease. Comparable to SHL in providing connected cardiac RPM with subscription analytics, but at a meaningfully smaller scale and narrower commercial footprint.
  • Eko Health: Eko Health produces FDA-cleared digital stethoscopes and AI-powered cardiac decision support, including the CORE 500 digital stethoscope with embedded ECG. Overlaps with SHL in AI-driven cardiac auscultation and rhythm analysis, but Eko focuses on clinician-side tools rather than direct-to-patient 12-lead monitoring.
  • Withings: Withings produces consumer health devices including the ScanWatch with embedded single-lead ECG and SpO2. Comparable to SHL in bringing clinical-grade vitals/ECG to the consumer home, but distributes through a consumer-electonics retail channel rather than payor/clinical contracting.

Broad incumbents

  • Boston Scientific (Preventice Solutions): Boston Scientific acquired Preventice Solutions, a US provider of ambulatory ECG monitors and connected cardiac diagnostics. Comparable to SHL in providing connected cardiac monitoring with central interpretation, but operates within Boston Scientific's much broader interventional and structural heart franchise.
  • Medtronic (Cardiac Diagnostics): Medtronic's Cardiac Diagnostics business — including the Reveal LINQ insertable cardiac monitor and connected diagnostics services — represents a large incumbent in remote cardiac monitoring with implantable and external devices. Comparable to SHL for ECG-based remote diagnostics, though Medtronic spans implantable CRM and broader hospital capital equipment.
  • Philips (BioTelemetry): Royal Philips acquired BioTelemetry to enter ambulatory cardiac monitoring (mobile cardiac telemetry, event monitoring, Holter). As a large medical-device incumbent, Philips competes with SHL in cardiac remote monitoring via established hospital and payor channels, but offers a much broader clinical product portfolio beyond SHL's specialty focus.
  • GE HealthCare (Marquette ECG): GE HealthCare's cardiology portfolio includes diagnostic ECG, cardiac ultrasound, and patient monitoring solutions widely deployed in hospitals. Comparable to SHL as a provider of clinical-grade ECG and cardiac monitoring infrastructure, though GE operates primarily in hospital capital equipment rather than payor-funded home telemedicine.

Direct peers

  • iRhythm Technologies: iRhythm Technologies is a US-based cardiac ambulatory monitoring company known for the Zio long-term ECG patch and AI-based arrhythmia detection. Comparable to SHL in serving cardiology patients with continuous remote ECG monitoring and central interpretation services, though SHL emphasizes 12-lead mobile ECG while iRhythm emphasizes patch-based extended wear.
  • AliveCor: AliveCor manufactures KardiaMobile, an FDA-cleared personal ECG device including the 6-lead KardiaMobile 6L, and is the closest direct competitor to SHL's SmartHeart in the consumer/clinical personal 12-6 lead ECG category. Both companies target cardiology-focused remote monitoring but AliveCor leans consumer/OTC while SHL anchors payor and clinical provider channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

SHL Telemedicine social profiles

Digital presence

SHL Telemedicine compliance and trust

Trust signal

Compliance4 records

SHL Telemedicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SHL Telemedicine leadership team

Management profile

Number of profiles

Profiles7 records

SHL Telemedicine subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

SHL Telemedicine funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SHL Telemedicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SHL Telemedicine

What does SHL Telemedicine do?

SHL Telemedicine provides remote cardiac and chronic disease monitoring services via its cloud-based telemedicine platform and FDA-cleared 12-lead ECG devices (SmartHeart, CardioSen'C, Cardio'B). The company operates 24/7 monitoring centers staffed by medical professionals that receive, interpret, and act on ECG and vital signs transmissions from patients at home. Its offerings are sold both as enterprise contracts to health insurers, payers, and hospitals and as OTC consumer devices via retail channels.

Is SHL Telemedicine a public or private company?

SHL Telemedicine is a public company. It is classified as public and is currently operating.

When was SHL Telemedicine founded?

SHL Telemedicine was founded in 1987. It employs 501 to 1,000 people.

Where is SHL Telemedicine based?

SHL Telemedicine is headquartered in Tel Aviv, Israel, in the Middle East region.

How does SHL Telemedicine make money?

Three revenue lines are on record. Telemedicine Services Revenue is the primary driver. The others are medical Device Sales and technology Licensing.

Who are SHL Telemedicine's main competitors?

Emerging players on record are Heartbeat Health, Biotricity, Eko Health and Withings. Broad incumbents are Boston Scientific (Preventice Solutions), Medtronic (Cardiac Diagnostics), Philips (BioTelemetry) and GE HealthCare (Marquette ECG). Direct peers are iRhythm Technologies and AliveCor.

Does SHL Telemedicine have an API?

No public API is recorded for SHL Telemedicine.

What industry is SHL Telemedicine in?

SHL Telemedicine's product category is Remote Cardiac and Chronic Disease Telemedicine Services. Its primary akta.pro industry code is HLALAGAB, Cardiology Telemedicine Platforms, with a secondary code of HLALADAD, Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Towards HealthcareTelehealth and Telemedicine Market Grows by 15.5% CAGR till 2034The global telehealth and telemedicine market is projected to grow from USD 247.81 billion in 2024 to USD 1,046.96 billion by 2034, expanding at a compound annual growth rate of 15.5%. This expansion is driven by technological advancements, increased adoption during the pandemic, and rising demand for remote care solutions such as AI diagnostics and wearable devices. Key industry players including Philips Healthcare, Teladoc Health, and Amazon are actively shaping the landscape through partnerships and product launches.PR NewswireGlobal Telemedicine Market to Grow at 11.3% CAGR Through 2030BCC Research has published a market report projecting the global telemedicine technologies market to grow from $146.9 billion in 2025 to $251.5 billion by 2030, representing a compound annual growth rate of 11.3%. The report identifies key market drivers including asynchronous telemedicine, IoT-enabled remote monitoring, chronic disease management, digital healthcare systems, and expanding insurance coverage for virtual care services.FinancialContent Business PageGlobal Telemedicine Technologies Markets Analysis Report 2025-2029 with Profiles of Leading Players - Siemens Healthineers, Koninklijke Philips, Teladoc Health, American Well, and SHL Telemedicine - RThe global telemedicine technologies market is projected to grow from $146.9 billion in 2025 to $251.5 billion by 2030, a CAGR of 11.3%. Growth is driven by increased virtual consultations, government investment, and digital health tools. Emerging technologies include AI and IoT-powered devices.GlobeNewswireTelemedicine Technology Markets Analysis Report 2025 | Market to Surpass $250 Billion by 2030, Driven by Virtual Consultations, Government Investment, and Emerging AI- and IoT-Powered Care PlatformsThe global telemedicine technologies market is projected to grow from $146.9 billion in 2025 to $251.5 billion by 2030, a CAGR of 11.3%. Growth is driven by virtual consultations, government investment, and AI/IoT-powered care platforms, with major players including Siemens Healthineers and Teladoc Health.PR NewswireSHL Telemedicine: Half-year results 2023 and Conference Call Scheduled for September 21, 2023SHL Telemedicine Ltd. announced it will release its Half-year 2023 financial results before market opens on September 21, 2023. The company will host a conference call on the same day at 4 pm CET / 10 am ET / 5 pm Israel Time, led by CEO Erez Nachtomy and CFO Amir Hai, to discuss the results with investors, journalists, and analysts. The press release and presentation slides will be available on the company website at 7:00 am CET on September 21, 2023.PR NewswireSHL Telemedicine to Commence Trading on NASDAQ Under the Symbol "SHLT"SHL Telemedicine Ltd. announced that its American Depositary Shares will commence trading on The NASDAQ Capital Market under the ticker symbol "SHLT" on April 3, 2023, while its ordinary shares continue listing on the SIX Swiss Exchange in Zurich. The SEC declared effective the company's registration statement under the U.S. Securities Exchange Act of 1934 in connection with the dual-listing, with Bank of New York Mellon appointed as depositary bank for the ADR program. The company stated the listing on a leading global exchange will increase access to retail and institutional investors and is expected to accelerate business operations and create shareholder value.PR NewswireSHL Telemedicine announces Confidential Submission of Draft Registration Statement for Proposed NASDAQ ListingSHL Telemedicine Ltd., a provider of personal telemedicine solutions listed on the SIX Swiss Exchange, has confidentially submitted a draft registration statement with the U.S. Securities and Exchange Commission for a proposed NASDAQ listing of American Depositary Shares. The company intends to maintain its Swiss listing while pursuing the parallel U.S. listing, pending completion of the SEC review process and NASDAQ approval. This dual-listing strategy would give SHL Telemedicine access to U.S. capital markets and potentially increase its visibility among American investors.PR NewswireSHL Telemedicine to present at Ladenburg Thalmann Virtual Technology Expo on December 7thSHL Telemedicine announced it will present virtually at the Ladenburg Thalmann Virtual Technology Expo on December 7, 2022. CEO Erez Nachtomy and CFO Amir Hai are scheduled to deliver the presentation regarding the company's telemedicine solutions. The event provides a platform for the company to update stakeholders on its operations and strategic direction.PR NewswireSHL Telemedicine bolsters its US Advisory Board as the growth of its SmartHeart® solution acceleratesSHL Telemedicine Ltd. announced the appointment of two new members, Dr. Kimberly J. Henderson and Dr. Joshua H. Atkins, to its US Advisory Board as part of its strategy to expand the use of its SmartHeart® technology in the United States. The company's CEO, Erez Nachtomy, expressed confidence that these key opinion leaders would provide valuable insight to support fast growth in the US market.PR NewswireFormer Prime Minister of Israel Ehud Barak to be appointed as Co-Chairman and leading partner of SHL's global growthSHL Telemedicine announced the appointment of former Israeli Prime Minister Ehud Barak as Co-Chairman and leading partner to drive its global growth. Barak intends to leverage his experience to expand SHL's operations, particularly in the US and Germany, alongside existing strategic partners like Mayo Clinic and CVS. The appointment is subject to approval by a Special General Meeting of Shareholders.